Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer.

Oncogene·2026
Same author

Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).

Journal of robotic surgery·2026
Same author

Patient-reported outcomes and experiences in outpatient vs inpatient robot-assisted radical prostatectomy: the BETTY trial.

BJU international·2026
Same author

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.

European urology oncology·2026
Same author

Digital Systematic Collection of Data for Patient-reported Outcome and Experience Measures Reveals Real-world Recovery Trajectories After Robot-assisted Radical Prostatectomy.

European urology focus·2025
Same author

Impact of intra-abdominal pressure with AirSeal<sup>®</sup> system on patient-reported outcomes and experience measurements after robot-assisted radical prostatectomy.

World journal of urology·2025

Related Experiment Video

Updated: Jul 11, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

Progensa PCA3 test for prostate cancer detection.

Alexandre de la Taille1

  • 1INSERM U841Eq07, Assistance Publique des Hôpitaux de Paris, Henri Mondor Hospital, Department of Urology, CHU Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France. adelataille@hotmail.com

Expert Review of Molecular Diagnostics
|September 26, 2007
PubMed
Summary

Elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) may indicate prostate cancer. A new PCA3 gene test helps identify patients needing repeat biopsies, potentially avoiding unnecessary procedures.

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jul 11, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

  • Urology
  • Oncology
  • Molecular Diagnostics

Background:

  • Elevated prostate-specific antigen (PSA) and abnormal digital rectal examination (DRE) results prompt prostate needle biopsies.
  • A significant proportion of initial prostate biopsies yield negative results, necessitating further investigation.
  • There is a clinical need for biomarkers to refine patient selection for repeat prostate biopsies.

Purpose of the Study:

  • To review the role of the PCA3 gene product as a biomarker for prostate cancer.
  • To present early clinical findings of the Progensa PCA3 test for patient selection.
  • To evaluate the utility of PCA3 in reducing unnecessary repeat prostate biopsies.

Main Methods:

  • Literature review of PCA3 gene expression in prostate tumors.
  • Analysis of initial clinical data from the Progensa PCA3 test.
  • Assessment of PCA3 test performance in identifying patients at high risk for prostate cancer.

Main Results:

  • The PCA3 gene product is overexpressed specifically in prostate tumor cells.
  • The Progensa PCA3 test utilizes this overexpression to assess prostate cancer risk.
  • Clinical data suggests the PCA3 test can aid in selecting patients for further biopsies.

Conclusions:

  • The PCA3 gene represents a promising biomarker for prostate cancer detection.
  • The Progensa PCA3 test offers a molecular approach to improve the diagnostic pathway.
  • Utilizing PCA3 testing may help avoid repeat prostate biopsies in select patient populations.